KPIs for Hold-Time: On-Time, Right-First-Time, and Repeat Findings



KPIs for Hold-Time: On-Time, Right-First-Time, and Repeat Findings

Published on 04/12/2025

KPIs for Hold-Time: On-Time, Right-First-Time, and Repeat Findings

In the pharmaceutical industry, maintaining the integrity and quality of products during hold times is critical for compliance with FDA, EMA, and MHRA regulations. This article aims to provide a comprehensive guide on the key performance indicators (KPIs) related to hold time studies, focusing on critical metrics such as on-time, right-first-time, and repeat findings for equipment holds, bulk holds, and intermediate holds.

Understanding Hold Times in Pharmaceutical Manufacturing

Hold time is the duration during which a product is maintained in a specific state before further processing or testing. In pharmaceutical manufacturing, there are inherent risks associated with extended hold times, including potential changes to product quality and degradation of microbiological attributes. Understanding the significance of hold times is essential, particularly in relation to quality assurance and regulatory compliance.

The United States Food and Drug Administration (FDA) defines hold times in the context of sterile products in 21 CFR Part 211. Additional guidelines provided in PIC/S and Annex 15 of the EU guidelines further emphasize the importance of establishing hold time protocols.

Categories of Hold Times

  • Equipment Hold Time: Refers to the period equipment must remain idle before it is cleaned, sterilized, or otherwise adjusted for production purposes.
  • Bulk Hold Time: The duration bulk pharmaceutical products can remain in their holding conditions before further processing, which requires stringent monitoring to ensure microbial limits are not exceeded.
  • Intermediate Hold Time: This pertains to stages of production where intermediate products are held before final processing, necessitating checks for compliance with endotoxin limit tests and microbial growth.

Key Performance Indicators (KPIs) for Hold Time

To ensure the highest standards of safety and quality, pharmaceutical businesses must develop, monitor, and maintain KPIs relating to hold times. The primary KPIs to evaluate include the following:

  • On-Time Performance: Measures whether hold times are adhered to without delay.
  • Right-First-Time (RFT): Ensures all processes associated with hold times are completed without the need for rework or remediation.
  • Repeat Findings: Tracks the consistency of results across multiple batches or studies, indicating stability or issues related to microbial contamination or product integrity.

1. On-Time Performance

Evaluating on-time performance involves use of robust record-keeping and documentation practices. Each instance of product holding should be logged accurately, identifying the starting and ending times of the hold as well as relevant environmental conditions.

Considerations for on-time performance may include:

  • Defining standard hold times based on validated studies.
  • Setting acceptable deviation thresholds that conform to regulatory expectations.
  • Regular audits of hold time logs to ensure compliance and identify trends.

2. Right-First-Time (RFT)

The RFT measurement focuses on the number of successful hold times executed without the necessity of reprocessing. To ensure a high RFT rate, consider implementing the following practices:

  • Standard Operating Procedures (SOPs) should be created and regularly updated
  • Training programs aimed at staff competency and regulatory compliance
  • Integration of automated systems for documentation and monitoring

These practices reduce the risk of errors and improve compliance with microbial limits and other requirements.

3. Repeat Findings

Repeat findings are essential in determining whether processes associated with hold times produce consistent results and comply with acceptance criteria. To minimize repeat findings, companies should:

  • Establish a thorough sampling plan that outlines clear expectations for testing and monitoring.
  • Engage in bioburden trending to identify any deviations that may necessitate corrective action.
  • Conduct regular cross-functional reviews with Quality Assurance (QA) to validate and improve results.

Documentation Requirements for Hold-Time Studies

Proper documentation is critical in validating hold time studies and ensuring compliance with regulatory frameworks. Documentation serves as evidence for successful hold-time execution and should include:

  • Detailed records of timing and any environmental conditions contributing to hold times.
  • Results of microbial limits testing, including both bioburden and endotoxin limits.
  • Any deviations from standard procedures, including the justification for such deviations and corrective actions taken.

Document control measures must be in place to protect the integrity of this information. It is crucial to ensure that all data is complete, accurate, and retrievable for regulatory inspections.

Acceptance Criteria and Regulatory Standards

To maintain compliance with global standards, various acceptance criteria must be established and adhered to during hold time studies. Acceptance criteria may involve:

  • Defined microbial limits that comply with 21 CFR Part 211 and other applicable regulations.
  • Defined thresholds for physical and chemical parameters relevant to hold times.
  • Endpoints for bioburden trending that indicate control over microbial contamination levels.

When defining these acceptance criteria, it is critical to reference standards set forth by organizations such as the WHO and recommended practices in Annex 15.

Implementing Hold-Time KPIs in Your Organization

The implementation of KPIs for hold-times requires a well-structured approach that integrates training, documentation, and ongoing monitoring. Below are steps essential for effective implementation:

  • Step 1: Training and Awareness: Enhance knowledge among staff dedicated to hold-time practices through targeted training sessions.
  • Step 2: Establishing SOPs: Create and distribute SOPs that detail hold-time practices, KPIs, and compliance measures.
  • Step 3: Utilize Automation Tools: Leverage technology to automate documentation and monitoring processes to ensure accuracy and efficiency in data collection.
  • Step 4: Regular Reviews and Audits: Schedule periodic reviews of hold-time performances and documentation practices to evaluate adherence and areas for improvement.

Conclusion

The establishment of KPIs for hold-time management is an essential part of maintaining compliance in pharmaceutical manufacturing. By focusing on on-time performance, right-first-time measures, and repeat findings, organizations can ensure that they are meeting the highest standards for product quality and safety. Streamlining documentation, establishing acceptance criteria based on regulatory guidelines, and implementing robust training frameworks are critical components driving successful hold-time studies. This proactive approach not only fosters regulatory compliance but also contributes to the overall improvement of product quality.

Constant vigilance and adherence to these standards will ultimately help strengthen the integrity of pharmaceutical products and the trust stakeholders have in the industry.